STAT+: Novartis wins approval for newborn malaria treatment

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Good morning, I hope everyone had a great holiday weekend. Let’s get into the news today.

The need-to-know this morning

• Foundering CAR-T therapy developer Cargo Therapeutics is being acquired and shut down. The buyer is Concentra Biosciences, the private company run by investor Kevin Tang.

Novartis wins approval for newborn malaria treatment

From my colleague Andrew Joseph: Novartis said today that Swiss regulators have approved its malaria medicine Coartem for newborns and young infants, extending a long-standing treatment to the smallest babies.

Continue to STAT+ to read the full story…